Layered rate controlling membranes for use in an electrotransport device

• US 6,163,720 A
• Filed: 12/03/1998
• Issued: 12/19/2000
• Est. Priority Date: 12/18/1997
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Gyory, J. Richard, Haak, Ronald P.
• Primary Examiner(s): Kennedy, Sharon
• Assistant Examiner(s): Hayes, Michael J
• Application Number:
  US09/204,820
• Time in Patent Office: 747 Days
• Field of Search: 604/19, 604/20, 424/447-449
• US Class Current: 604/20
• CPC Class Codes: A61N 1/0436 Material of the electrode
• CPC Class Codes: A61N 1/0444 Membrane
• CPC Class Codes: A61N 1/0448 Drug reservoir

Abstract

The disclosed invention relates to an improved electrotransport device. The improvement relates to a membrane assembly including a low porosity membrane adhered or sealed to one or two high porosity membranes. The high porosity membranes protect the low porosity membrane from being damaged by components or contaminates on the body surface and/or in the drug reservoir which can lead to undesirable passive flux and/or insufficient iontophoretic flux. As a result, the electrotransport device having the membrane assembly more reliably, precisely, and accurately delivers drug and/or therapeutic agent through the body surface by electrotransport.

Claims

1. An electrotransport device for delivering a therapeutic agent through a body surface comprising:

a controller,

a power source,

a counter electrode assembly, and

at least one donor electrode assembly including an electrode, a donor reservoir containing the agent, and a membrane assembly located on the body surface distal side of the donor electrode assembly, said membrane assembly comprising;

a first membrane having a first average pore size, porosity, pore size distribution, and spatial pore distribution affixed to

a second membrane having a second average pore size, porosity, pore size distribution, and spatial pore distribution,

wherein the first porosity is less than the second porosity.

2. The electrotransport device of claim 1 wherein said second membrane is located between said reservoir and said first membrane.

3. The electrotransport device of claim 1 wherein said first membrane is located between said reservoir and said second membrane.

4. The electrotransport device of claim 1 wherein said membrane assembly further includes a third membrane having a third average pore size, porosity, pore size distribution, and spatial pore distribution and said first membrane is affixed between said second membrane and said third membrane, wherein said third porosity is greater than said first porosity.

5. The electrotransport device of claims 1, 2, 3, or 4, wherein said first membrane is sufficiently porous to permit at least a therapeutically effective flux of said agent.

6. The electrotransport device of claims 1, 2, or 3 wherein said first porosity is less than or equal to about 1% and said second porosity is greater than or equal to about 10%.

7. The electrotransport device of claim 4 wherein said first porosity is less than or equal to about 1% and said second and third porosities are greater than or equal to about 10%.

8. The electrotransport device of claims 1, 2, or 3 wherein said first porosity is less than or equal to about 0.1% and said second porosity is greater than or equal to about 20%.

9. The electrotransport device of claim 4 wherein said first porosity is less than or equal to about 0.1% and said second and third porosities are greater than or equal to about 20%.

10. The device of claims 1, 2, 3, or 4 having a body surface contact area of about 2 to about 30 cm², wherein said first average pore size is in the range of about 0.22 to about 5.0 microns and the said first pore density is in the range of about 1×

10³ to about 1×

10⁶ pores/cm².

11. The device of claim 10 wherein said first pore density is in the range of about 1×

10³ to about 1×

10⁴ pores/cm².

12. The device of claims 1, 2, or 3 wherein the first average pore size and the second average pore size are in the range of about 1 mm to about the molecular size of the agent.

13. The device of claim 4 wherein the first average pore size, the second average pore size and the third average pore size are in the range of about 1 mm to about the molecular size of the agent.

14. The device of claims 1, 2, 3, or 4 wherein the first average pore size is in the range of about 0.01 microns to about 200 microns.

15. The device of claims 1, 2, or 3 wherein the first average pore size is about 1 micron and the second average pore size is about 5.0 microns.

16. The device of claim 4 wherein the first average pore size is about 1 micron and the second average pore size and the third average pore size are about 5.0 microns.